| News

docdok.health involved in coronavirus research project


A research project is investigating the improvement in the condition of patients who have been hospitalized due to COVID-19. docdok.health based in Basel is contributing the smartphone app for the project.

img: docdok.health

According to a media release, the new research project on the effects of coronavirus infection has been launched by the CAir Konsortium, which includes the University Hospital Zurich (USZ) and the Swiss Federal Institute of Technology in Zurich (ETH) in addition to docdok.health, among others. The media release from docdok.health states that the project is also being supported by AstraZeneca Switzerland. With this, the research partners hope to investigate “the improvement in symptoms, lung function and quality of life in persons who have been hospitalized due to a coronavirus (specifically SARS-CoV-2) infection and the related severe lung disease to lung failure.”

For this, patients were surveyed after being discharged from the USZ using a docdok.health smartphone app, and a home monitoring system was implemented to follow-up patients. This system consists of “a lung function measuring device, an activity wristband, an air quality monitor, and a smartphone.” This system, called CAir Desk, was originally developed for the long-term care of patients with chronic lung disease.

Physicians from the USZ are able to study the data from both approaches at their place of work. For this, the data is prepared by docdok.health and presented clearly on an appropriate user interface. The company based in Basel was founded in 2017 and develops solutions to drive forward utility-based healthcare. The platform they have developed can collect and prepare patient-generated health data. This platform is already in use in five countries both for routine clinical applications and studies.

Share this article

Sign up to receive our newsletter in your inbox.

You may also be interested in

Novartis Campus
Basel Area Business & Innovation, Switzerland Innovation Park

Switzerland Innovation Park Basel Area Site Novartis Campus

We are happy to present our latest addition to the Switzerland Innovation Park Basel Area: Our site on the Novartis Campus dedicated to digital health provides a focal point to a unique community of digital healthcare experts.

Read More
Basel Area Business & Innovation, Switzerland Innovation Park

The innovation and enterprise campus GRID is filling up

Two institutes from the University of Basel and a pharmaceutical company are relocating to the GRID innovation and enterprise campus, which is currently under construction at BaseLink in Allschwil. The new building will also contain the headquarters of the Switzerland Innovation Park Basel Area in future.

Read More
Basel Area Business & Innovation, Innovation

Artidis ends successful study

Artidis, a startup from Basel, has developed a nanotechnology platform that can be used for cancer diagnosis, among other things. The platform has now been tested in a study that was able to achieve its primary endpoint.

Read More
Basel Area Business & Innovation, Innovation

Startup Academy celebrates anniversary

Startup Academy is on the road to success ten years after being founded. The initiative has supported 280 startups to date. The project was originally started in Basel and is now represented at several locations in Switzerland with plans for further growth.

Read More
Basel Area Business & Innovation, Invest

Syngenta grows strongly and stays true to Basel

Syngenta AG, Adama and Sinochem are to be united under the umbrella of the new Syngenta Group. The group is headquartered in Basel and employs around 48,000 staff across over 100 countries.

Read More
Basel Area Business & Innovation, Innovation

Tolremo raises additional funding

The Muttenz-based biotechnology company Tolremo Therapeutics has raised an additional 4.7 million Swiss francs as part of a financing round. The company develops cancer therapies for precision medicine and is now driving forward clinical development.

Read More
1 2 3 31

Do you have a question? We'd like to hear from you.